Background Non-muscle-invasive bladder cancer (NMIBC) is characterized by high recurrence rates, highlighting the need for effective, non-invasive diagnostic and risk stratification tools. Although urinary biomarkers are increasingly used worldwide, molecular data specific to Chinese NMIBC populations remain limited. T...
Zu-Gang Sun, Run Xie, Jian Pan et al.· Frontiers in Oncology· 0 citations
In this nonrandomized clinical trial, bicistronic CD19/CD22 CAR T-cell therapy induced high rates of minimal residual disease-negative remission, with durable EFS in pediatric B-ALL, and support further evaluation in prospective trials.
Xinyu Wan, Yan-Jing Tang, Jiao-Yang Cai et al.· JAMA Oncology· 1 citation
The progress in the treatment modalities for SCLC is focused on and future perspectives involving novel therapeutic combinations, assessment of new targets, and strategies to overcome treatment resistance are discussed.
Xiangwei Cheng, Weibin Lv, Linfeng Wu et al.· Journal of Cancer Research a...· 0 citations
We use cookies to run the site and, with your consent, for analytics and to show ads.
See our Cookie Policy.